NASDAQ : PTCT

PTC Therapeutics, Inc.

$75.8 USD

-$1.02 (-1.33%)

Volume
1.76M
Average Volume
1.83M
Market Capitalization
$6.29B
P/E Ratio
-32.48
Dividend Yield
0.00%
Price Target
$94.00
Year High
$90.87
Year Low
$43.18
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.44
Company Overview

NASDAQ

Matthew Klein

Biotechnology

Healthcare

PTCT

991

US

USD

https://www.ptcbio.com

908 222 7000

69366J200

0001070081

Liquidity Metrics

-2.19

2.44

2.36

0.90

0.00

Sales & Valuation

$1.73B

7.60

-34.66

-23.81

-3.20

Profitability

$7.78

$682.64M

-22.58%

-28.49%

99.84%

-6.51%

P/E Metrics

-32.48

0.25

0.25

Analyst Price Target & Rating

$94.00

$130.00

$85.00

Sell

2/5

26 Analysts

-19.36%

Financial Health Scores

0.46

1/9

$1.33B

$2.87B

$3.05B

-$166.56M

Key Metrics (TTM)

$5.93B

7.17

-49.63

2.44

99.84%

-2.38%

-2.95%

-4.14%

197 days

Company Executives
Name Title
Allan Steven Jacobson Co-Founder & Independent Director
Lee Golden Executive Vice President & Chief Medical Officer
Matthew Klein Chief Executive Officer & Director
Neil Almstead Chief Technical Operations Officer
Eric Pauwels Chief Business Officer
Pierre Gravier Chief Financial Officer
Christine Utter Senior Vice President, Chief Accounting Officer & Head of People Services
Linda Montella Carter Senior Vice President & Chief Information Officer
Ellen Cavaleri Head of Investor Relations
Jane Baj Vice President of Corporate Communications
Mark Elliott Boulding Executive Vice President & Chief Legal Officer
Poll Results

No votes yet today — be the first to share your view!

About PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionall ... y commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.

PTC Therapeutics, Inc. $PTCT Shares Purchased by Fifth Third Bancorp

2026-07-25 04:05:34

Fifth Third Bancorp increased its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 12,362.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,447 shares of the biopharmaceutical company's stock after acquiring an additional 17,307 shares

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director

2026-07-23 07:00:00

CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as a new independent director, effective July 22, 2026.

PTC Therapeutics, Inc. $PTCT Shares Purchased by Bessemer Group Inc.

2026-07-22 03:40:37

Bessemer Group Inc. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 21,814.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,813 shares of the biopharmaceutical company's stock after buying an additional 52,572 shares during the quarter. Bessemer

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

2026-07-16 08:00:00

WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, July 30, 2026, at 4:30 p.m.

What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million

2026-07-13 19:28:52

The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25. The disposition represented 4% of the insider's direct common stock holdings.

Reasons Why Investors Should Consider Betting on PTC Stock Now

2026-07-10 15:16:06

PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.

Stocks Look Shaky, But This Sector is Booming (Biotech)

2026-07-09 14:06:06

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know

2026-07-08 13:01:07

PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Frequently Asked Questions

What is the current PTC Therapeutics, Inc. (PTCT) stock price?

PTC Therapeutics, Inc.(NASDAQ:PTCT) stock price is $75.8 in the last trading session. During the trading session, PTCT stock reached the peak price of $90.87 while $43.175 was the lowest point it dropped to. The percentage change in PTCT stock occurred in the recent session was --1.33% while the dollar amount for the price change in PTCT stock was -$1.02.

PTCT's industry and sector of operation?

The NASDAQ listed PTCT is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of PTCT?

Allan Steven Jacobson | Co-Founder & Independent Director
Lee Golden | Executive Vice President & Chief Medical Officer
Matthew Klein | Chief Executive Officer & Director
Neil Almstead | Chief Technical Operations Officer
Eric Pauwels | Chief Business Officer

How many employees does PTCT have?

Number of PTCT employees currently stands at 991. PTCT operates from 500 Warren Corporate Center Drive, Warren, NJ 07080, US.

Link for PTCT official website?

Official Website of PTCT is: https://www.ptcbio.com

How do I contact PTCT?

PTCT could be contacted at phone #908 222 7000 and can also be accessed through its website. PTCT operates from 500 Warren Corporate Center Drive, Warren, NJ 07080, US.

How many shares of PTCT are traded daily?

The average number of PTCT shares traded daily for last 3 months was 1.83M.

What is the market cap of PTCT currently?

The market value of PTCT currently stands at $6.29B with its latest stock price at $75.8